Table 2.
Once-daily administration of MIN (50 mg/kg, q.d. i.p.), but not VPA (100 mg/kg, q.d. i.p.), during the acute infection period significantly reduced the proportion of mice with tonic extension seizure and increased the rate of survival after i.v. PTZ infusion 42 DPI. For reference, sham-infected, age-matched C57/Bl6J mice were included in the evaluation. TMEV titer was 2.5 × 105 PFU. Importantly, mice in the MIN treatment group were not significantly different from age-matched, Sham-infected C57Bl/6J mice.
| Treatment Group | % with Tonic Extension Seizure | % Survival Post-i.v. PTZ |
|---|---|---|
| Sham-infected (n = 7) | 14.3% | 85.7% |
| VEH, TMEV-infected (n = 8) | 75% # | 0% # |
| MIN (50 mg/kg, q.d.), TMEV-infected (n = 8) | 25%* | 62.5%* |
| VPA (100 mg/kg, q.d.), TMEV-infected (n = 6) | 83.3% # | 17.7% # |
*
Indicates significantly different from VEH-treated, TMEV-infected mice, p < 0.05.
#
Indicates significantly different from Sham-infected mice, p < 0.05.